AI drug developer Pathos raises $237 million at a $3 billion valuation
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Pathos raised $237 million in a Series E round led by Bristol Myers Squibb, valuing the company at about $3 billion. It will use Tempus AI datasets and a BMS partnership to expand beyond oncology into neurological diseases, initially focusing on Alzheimer’s treatments.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu